Labcorp (LH) to Release Earnings on Thursday

Labcorp (NYSE:LH - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect Labcorp to post earnings of $4.12 per share and revenue of $3.49 billion for the quarter. Labcorp has set its FY 2025 guidance at 15.700-16.400 EPS.

Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.11. Labcorp had a net margin of 5.55% and a return on equity of 15.27%. The company had revenue of $3.35 billion during the quarter, compared to analyst estimates of $3.41 billion. During the same quarter last year, the firm posted $3.68 EPS. The business's revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts expect Labcorp to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Labcorp Stock Performance

NYSE:LH opened at $245.94 on Thursday. Labcorp has a twelve month low of $205.98 and a twelve month high of $265.72. The company has a current ratio of 1.84, a quick ratio of 1.60 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average of $253.73 and a 200-day moving average of $243.44. The firm has a market cap of $20.58 billion, a price-to-earnings ratio of 28.43, a price-to-earnings-growth ratio of 1.56 and a beta of 0.82.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Thursday, August 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.17%. Labcorp's dividend payout ratio (DPR) is 33.29%.

Wall Street Analysts Forecast Growth

LH has been the subject of several recent analyst reports. HSBC cut shares of Labcorp from a "buy" rating to a "hold" rating and set a $260.00 target price for the company. in a report on Thursday, July 10th. Evercore ISI raised their target price on shares of Labcorp from $260.00 to $285.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Barclays reiterated a "cautious" rating on shares of Labcorp in a report on Wednesday, June 25th. Truist Financial raised their target price on shares of Labcorp from $274.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Finally, Redburn Atlantic initiated coverage on shares of Labcorp in a report on Wednesday, April 2nd. They issued a "buy" rating and a $276.00 target price for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Labcorp currently has a consensus rating of "Moderate Buy" and an average target price of $276.38.

Insiders Place Their Bets

In related news, EVP Brian J. Caveney sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $247.00, for a total transaction of $494,000.00. Following the transaction, the executive vice president owned 30,067 shares of the company's stock, valued at approximately $7,426,549. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam H. Schechter sold 6,105 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $248.73, for a total transaction of $1,518,496.65. Following the transaction, the chief executive officer directly owned 98,962 shares in the company, valued at approximately $24,614,818.26. The trade was a 5.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,834 shares of company stock valued at $2,928,714 over the last ninety days. Insiders own 0.84% of the company's stock.

Hedge Funds Weigh In On Labcorp

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC raised its position in Labcorp by 7.9% during the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock valued at $565,000 after acquiring an additional 177 shares in the last quarter. Brighton Jones LLC bought a new position in Labcorp during the fourth quarter valued at approximately $991,000. Finally, Goldman Sachs Group Inc. raised its position in Labcorp by 52.2% during the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock valued at $82,353,000 after acquiring an additional 121,304 shares in the last quarter. Institutional investors own 95.94% of the company's stock.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.